1268241-76-4

Basic information

• Product Name: 12-bromo-8-oxa-3,5,10-triazatricvclor[7.4.0.0²'⁷]trideca-1 ⁽⁹⁾, 2⁽⁷⁾,10,12-tetraene-4,6-dione
• Synonyms: 12-bromo-8-oxa-3,5,10-triazatricvclor[7.4.0.0²'⁷]trideca-1 ⁽⁹⁾, 2⁽⁷⁾,10,12-tetraene-4,6-dione
• CAS NO: 1268241-76-4
• Molecular Weight: 282.053
• Mol File: 1268241-76-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 12-bromo-8-oxa-3,5,10-triazatricvclor[7.4.0.0²'⁷]trideca-1 ⁽⁹⁾, 2⁽⁷⁾,10,12-tetraene-4,6-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 12-bromo-8-oxa-3,5,10-triazatricvclor[7.4.0.0²'⁷]trideca-1 ⁽⁹⁾, 2⁽⁷⁾,10,12-tetraene-4,6-dione(1268241-76-4)
• EPA Substance Registry System: 12-bromo-8-oxa-3,5,10-triazatricvclor[7.4.0.0²'⁷]trideca-1 ⁽⁹⁾, 2⁽⁷⁾,10,12-tetraene-4,6-dione(1268241-76-4)

Safety Data

• Hazardous Substances Data: 1268241-76-4(Hazardous Substances Data)

Upstream product

• 405224-23-9 5-bromo-2-chloropyridine-3-carbonitrile 

Relevant articles and documents

PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA

The present invention relates to a compound of formula (I), or its pharmaceutically acceptable salt. The compound, or its pharmaceutically acceptable salt, is useful as a PI3K inhibitor and therefore in therapy. In particular, the compound, or its pharmaceutically acceptable salt, has utility in the treatment of B cell lymphoma.

TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS

The invention relates to a compound of formula I: (I) or a pharmaceutically acceptable salt thereof, wherein each R3 is independently selected from H, halo, fluorinated C1-C10 alkyl, -O-C1-C10 alkyl, -NH-C1-C10 alkyl, -S-C1-C10 alkyl, -O-fluorinated C1-C10 alkyl, -NH-acyl, -NH-C(O)-NH-alkyl, -C-(O)- NH-alkyl, with the proviso that at least one of R3 is not H.

COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT

The invention relates to a pharmaceutical composition comprising a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one second agent selected from the group consisting of signal transduction pathway inhibitors, tumour immunotherapeutics, agents inhibiting the BCL2 family of proteins, agents inhibiting Mcl-1, proteasome Inhibitors, poly (ADP-ribose) polymerase (PARP) Inhibitors, aromatase inhibitors, conventional cytotoxic agents or a miscellaneous agent selected from abiraterone, ARN-509 and MYC inhibitors.